Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2024

This “Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Fms-like tyrosine kinase 3 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Fms-like tyrosine kinase 3 inhibitors Understanding

Fms-like tyrosine kinase 3 inhibitors: Overview

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase (RTK), a membrane-bound receptor with an intrinsic tyrosine kinase activity that is highly expressed in hematopoietic stem/progenitor cells and regulates hematopoietic differentiation and proliferation. Activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML). FLT3 is made up of 5 functional domains: an immunoglobulin-like extracellular domain, a transmembrane domain, a juxtamembrane domain (JMD), a tyrosine kinase domain (TKD), and a small C-terminal domain. FLT3 is a promising molecular target in a subset of AML cases, and the therapeutic effects of FLT3 inhibitors have been reported in AML patients with FLT3 mutations. The exploration of small-molecule inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new AML therapy. A number of resistance mechanisms to FLT3 inhibitors have been identified in preclinical and clinical studies, including acquired FLT3 resistance mutations, other gene mutations such as NRAS, and altered protein expression such as that of FL, AXL kinase, Pim kinase, or FGF2.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Fms-like tyrosine kinase 3 inhibitors R&D. The therapies under development are focused on novel approaches for Fms-like tyrosine kinase 3 inhibitors.

Fms-like tyrosine kinase 3 inhibitors Emerging Drugs Chapters

This segment of the Fms-like tyrosine kinase 3 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fms-like tyrosine kinase 3 inhibitors Emerging Drugs

CG-806: Aptose Biosciences CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor. This small molecule, in-licensed from Crystal Genomics in Seoul, South Korea, demonstrates potent inhibition of wild type and all mutant forms of FLT3 (including internal tandem duplication, or ITD, and mutations of the receptor tyrosine kinase domain and gatekeeper region), cures animals of acute myeloid leukemia (AML) tumors in the absence of toxicity in murine xenograft models. The drug is in Phase I/II clinical studies for the treatment of CLL&NHL.

Quizartinib: Daiichi Sankyo Company Quizartinib is an orally administered, small molecule FLT3 kinase inhibitor. Quizartinib was approved by the Ministry of Health, Labor and Welfare (MHLW) of Japan under the brand name of VANFLYTA for the treatment of adult patients with relapsed/refractory FLT3-ITD AML on June 18, 2019. Quizartinib is currently being studied alone or in combination with other agents as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in adult and pediatricpopulations.

Fms-like tyrosine kinase 3 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Fms-like tyrosine kinase 3 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Fms-like tyrosine kinase 3 inhibitors

There are approx. 25+ key companies which are developing the Fms-like tyrosine kinase 3 inhibitors. The companies which have their Fms-like tyrosine kinase 3 inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Quizartinib.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Fms-like tyrosine kinase 3 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fms-like tyrosine kinase 3 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Fms-like tyrosine kinase 3 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fms-like tyrosine kinase 3 inhibitors drugs.

Fms-like tyrosine kinase 3 inhibitors Report Insights

• Fms-like tyrosine kinase 3 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fms-like tyrosine kinase 3 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Fms-like tyrosine kinase 3 inhibitors drugs?
• How many Fms-like tyrosine kinase 3 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Fms-like tyrosine kinase 3 inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fms-like tyrosine kinase 3 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fms-like tyrosine kinase 3 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aptose Biosciences
• Daiichi Sankyo Company
• Celon Pharma
• AROG Pharmaceuticals
• Pfizer
• Ascentage Pharma
• Pharos I&BT Co
• Novartis Oncology
• Exelixis
• Ipsen

Key Products

• CG-806
• Quizartinib

Research program: small molecule anti-cancer therapeutics- Crenolanib

• Olverembatinib
• PHI-101
• Midostaurin
• Cabozantinib

This product will be delivered within 2 business days.